Title: Dr. Neil Tolson Head, In Commerce Substances Unit 1 New Substances Assessment and Control Bureau
1Dr. Neil TolsonHead, In Commerce Substances
Unit 1New Substances Assessment and Control
Bureau
- The In Commerce List
- EnviroPharm 2009
- O1 October 2009
2Introduction
- Background
- Revision Process
- Communications Strategy for Revision Process
- Next Steps
- Contact Information and Website Address
3Background What is the In Commerce List
- The In Commerce List (ICL) consists of
approximately 9,000 substances in products
subject to the regulations of the Food and Drugs
Act that were in commerce between 01 Jan. 1987
and 13 Sept. 2001. - The current list was created in 2001 from records
in HC commodity groups. - Each entry has a maximum of three pieces of
information CAS Name, CAS Number and alternate
name. - Substances on the ICL are defined as new
substances under CEPA, i.e., they are not on the
DSL, however, under the current policy NSNR
requests will not be made for ICL substances
4Background The Need to Revise the ICL
- The current list has a number of deficiencies,
including - incorrect information, e.g., CAS numbers do not
match CAS names - omissions substances in commerce that were not
in HC records duplications the same substance
may be present under a different name - substances on the DSL
- lack of information most substances do not have
a CAS Number and CAS Name the list does not
contain structures, use patterns, or annual
volumes
5Background Management of ICL Substances
- Revision of the current ICL
- 2. Categorization/prioritization substances on
the revised ICL - 3. Assessment of risks of ICL substances to
humans (indirect exposure) and to the environment - 4. Proposal of risk mitigation measures, where
required
6Revision Process Multi-stakeholder Consultations
- The ICL technical subcommittee was established in
2007 under the multi-stakeholder Environmental
Assessment Working Group (EAWG). - The ICL subcommittees work has focused on what
substances should be nominated to the revised
ICL, what substances should be excluded, and the
process on how to submit nominations to a revised
ICL.
7Revision Process Nomination Process
- The revision of the ICL will be based on a
two-phase nomination process - Industry will submit information to HC to enable
the identification of each substance - For substances on the current ICL, no proof of in
commerce required. Substances not on the current
ICL will require proof of in commerce
8Revision Process Additions to the Current ICL
- Health Canada is accepting requests for
additions to the ICL until the nomination process
for revision of the ICL is initiated. - To date approximately 300 substances have been
added to the ICL following receipt requests and
assessment of the supporting information from
manufactures and importers. - Enquiries on the process for submitting a
request for additions to the ICL should be
addressed to the In Commerce Substances Unit 1
(see slide on contact information).
9 Revision Process Verification of Substance
Identity To Date
- The identity of 2200 substances on the current
ICL, approximately 25 of the List, has been
verified through a contract with Chemical
Abstract Services (CAS). These substances will be
added directly to the revised ICL. -
10 Communications Strategy Components
- A communications strategy for stakeholders and
the public has been prepared. The strategy
includes distribution of the Guidance Document
presentations to industry HC website for the
ICL and, an e-mail address and telephone line
for enquiries
11Communications StrategyGuidance Document For
Nomination Process
- A comprehensive Guidance Document on the
nomination process will be available on line. It
will contain information on what to nominate, how
to nominate and nomination forms.
12 Communications Strategy HC Website
- An updated ICL website has been activated,
effective June 2009. A subscribers option is
being be added for stakeholders and the
subscribers will be notified automatically by
e-mail of updates to the website.
13Next Steps Nomination Process
- Conclude consultations
- Initiate the communications strategy, including
production of the Guidance Document - Launch the first phase of the nomination process
14Next Steps Prioritization Process
- Preliminary work is being conducted by Health
Canada on approaches to prioritize substances on
the ICL. -
15Contact Information
- Neil Tolson
- Head, In Commerce Substances Unit 1
- New Substances Assessment and Control Bureau
- 123 Slater Street, 5th Floor
- Ottawa Ontario K1A 0K9
- PL 3505A
- neil_ tolson _at_hc-sc-gc.ca
- Tel. 613-941-0144
16Website Address
- Information on the ICL, including substances on
the current list, can be obtained from the
following website - http//www.hc-sc.gc.ca/ewh-emt/contaminants/perso
n/impact/list/index-eng.php
17Questions?